Drug Trial Radar · NCT05796440
A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)
Last checked: Nov 19, 2026Latest source record: Feb 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
60
Planned (sponsor's estimate)
Start
Aug 1, 2023
Primary completion
Mar 2028
Study completion Apr 2028
Sponsor
- Lead sponsor
- Lumos PharmaIndustry
- Sponsor type
- Industry
- First posted
- Apr 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 years, up to 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-national trial. The trial aims to study the long-term safety of LUM-201 in subjects with Idiopathic Pediatric Growth Hormone Deficiency (iPGHD). This study will also assess pharmacodynamics and efficacy response to therapy with LUM-201.
Conditions
- Growth Hormone Deficiency
Interventions
LUM-201Drug
Administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse eventsTime frame: Day 1 to Month 36
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
University of Iowa
Iowa City, Iowa
UMass Memorial Medical Center
Worcester, Massachusetts
Children's Mercy Hospital
Kansas City, Missouri
University of South Carolina
Charleston, South Carolina
Texas Tech University Health Sciences Center
Amarillo, Texas
Seattle Children's Hospital
Seattle, Washington
Canberra Hospital
Garran, Australian Capital Territory, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.